Fluorouracil paste treatment of thin basal cell carcinomas

Epstein, E.

doi:10.1001/archderm.121.2.207

Cited by 25 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study using 25% topical 5-FU in petrolatum under occlusion for 3 weeks found a 5-year cure rate of 79% for superficial BCCs. 104 Imiquimod 5% cream was approved by the FDA for treatment of superficial BCCs of the face, neck, trunk, and extremities in 2004. Imiquimod may stimulate innate and acquired immunity by inducing transcription of interferon alpha and gamma, and tumor necrosis factor alpha after binding to toll-like receptor 7.…”

Section: Topical Therapymentioning

confidence: 99%

Consensus for Nonmelanoma Skin Cancer Treatment

Kauvar

Cronin

Roenigk

et al. 2015

Dermatologic Surgery

130

View full text Add to dashboard Cite

show abstract

Section: Topical Therapymentioning

confidence: 99%

Consensus for Nonmelanoma Skin Cancer Treatment

Kauvar

Cronin

Roenigk

et al. 2015

Dermatologic Surgery

130

View full text Add to dashboard Cite

show abstract

“…5-FU has been shown to be particularly effective for treating thin (superficial) BCC when conventional methods are impractical (e.g., in the cases of multiple lesions or at difficult treatment sites) or when used in combination with curettage and electrodessication [6,86]. …”

Section: Classical Therapy Of Nmscsmentioning

confidence: 99%

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Fernandes

Santos²,

Kovačević³

et al. 2017

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Neoplastic skin lesions are multifocal, diffuse skin infiltrations of particular relevance in the differential diagnosis of ulcerative, nodular, or crusting skin lesions. Nonmelanoma skin cancers (NMSCs), namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and also actinic keratosis (AK), are the most common malignant tumors in humans. BCCs do not proliferate rapidly and most of the times do not metastasize, while SCCs are more infiltrative, metastatic, and destructive. AKs are precursor lesions of cutaneous SCCs. The classical therapy of NMSCs makes use of photodynamic therapy associated with chemotherapeutics. With improved understanding of the pathological mechanisms of tumor initiation, progression, and differentiation, a case is made towards the use of targeted chemotherapy with the intent to reduce the cytotoxicity of classical treatments. The present review aims to describe the current state of the art on the knowledge of NMSC, including its risks factors, oncogenes, and skin carcinogenesis, discussing the classical therapy against new therapeutic options.

show abstract

“…Because the cure rate is considered lower than surgery or radiation therapy, the National Comprehensive Cancer Network (NCCN) guidelines reserve this therapy in patients with low-risk sBCC where surgery or radiation is contraindicated or impractical [20]. Because the percutaneous penetration of 5-FU is variable and limited [29][30][31], its use is recommended only for sBCC and not other histologic types of BCC. • Topical 5-FU is applied twice daily for no <6 weeks if not occluded or combined with curettage.…”

Section: -Fluorouracilmentioning

confidence: 99%

“…• A small number of randomized controlled trials suggests that retinoids may have a role in the prevention of skin cancer in OTR [29,33,34]. Systemic retinoids can be considered in OTRs with a history of numerous SCCs, aggressive SCC, and when there occur along with actinic keratoses and warts [35].…”

Section: Retinoidsmentioning

confidence: 99%

Skin Cancer and the Solid Organ Transplant Recipient

Patel

Liégeois

2008

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Organ transplant recipients (OTRs) are living longer in setting of improved medical immunosuppression. The most common late post-transplant complication includes a variety of malignant and premalignant cutaneous tumors. Aggressive skin cancers are common in this population. Clinical and pathologic correlation is essential in choosing the appropriate treatment for the various subtypes of skin cancer in OTR. Approaches include risk assessment for other skin tumors, treatment of malignancy, and prevention. Few prospective or retrospective studies with multivariate analysis exist and therefore opinion largely dominates treatment recommendations. Treatment aims: (i) The mainstay of treatment focuses on total removal (excision) or mechanical destruction of the tumor. In the appropriate clinical scenario, a skin cancer should be removed or treated fully. (ii) Treatment modality is dependant upon low- vs high-risk tumors and tumor type. (iii) Utilize excision with margin control, either by permanent or frozen (Mohs) technique, for large tumors and tumors in high-risk sites. (iv) New treatment modalities include immune modulators, topical photodynamic therapy, and drugs targeting genetic defects. (v) Education on skin cancer prevention should target all the age groups.

show abstract

Fluorouracil paste treatment of thin basal cell carcinomas

Cited by 25 publications

References 0 publications

Consensus for Nonmelanoma Skin Cancer Treatment

Consensus for Nonmelanoma Skin Cancer Treatment

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Skin Cancer and the Solid Organ Transplant Recipient

Contact Info

Product

Resources

About